Moderna's stock price plummeted 20% in early trading! Sales of two flagship products were disappointing, leading to a significant cut in the annual revenue forecast.

① The American vaccine manufacturer Moderna expects revenue for 2025 to be between 1.5 billion and 2.5 billion USD due to a slowdown in demand for its two main products, which is significantly lower than the previously expected 2.5 billion to 3.5 billion USD; ② Moderna's stock price fell 20% due to the lowered revenue expectations, with its CEO stating that the adjustment reflects increased competition in the COVID-19 vaccine market, delayed infrastructure development, and a decline in vaccination rates.

cls.cnJan 13 23:01

Stocks Making the Biggest Moves Midday: Nvidia, Quantum Computing Stocks, Moderna and More

CNBC42minutes ago

Trending Stocks Today | Phio Pharmaceuticals Surges 323.96%

January 13th - US stocks trending in regular trading hours.Gainers: $Phio Pharmaceuticals(PHIO.US)$ surges 323.96% to $7.17 with a turnover of $1.3 billion. $Salarius Pharmaceuticals(SLRX.US)$

Futu News01:05

Crude Oil Surges 3%; Abercrombie & Fitch Shares Plunge

Benzinga01:04

Top Stock Movers Now: Moderna, Macy's, Valero Energy, and More

Yahoo Finance00:57

Top Midday Stories: Moderna Shares Fall After 2025 Revenue Guidance Cut; Cleveland-Cliffs Reportedly Teams Up With Nucor in Potential Bid for US Steel

MT Newswires00:54